Reported toxicity that was significantly more frequent in the MPT group
| Toxicity . | Grade 1 or 2, no. (%) of patients . | Grade 3 or 4, no. (%) of patients . | P . | ||
|---|---|---|---|---|---|
| MPT . | MP . | MPT . | MP . | ||
| Constipation | 66 (37) | 47 (13) | 11 (6) | 5 (3) | .003 |
| Neuropathy | 39 (21) | 9 (6) | 10 (6) | 1 (1) | .001 |
| Nonneuropathy neurologic toxicity* | 24 (14) | 19 (11) | 14 (8) | 3 (2) | .022 |
| Exanthema | 16 (9) | 8 (4) | 4 (2) | 0 | .019 |
| Nonhematologic, altogether | 84 (47) | 54 (49) | 70 (40) | 33 (19) | .001 |
| Toxicity . | Grade 1 or 2, no. (%) of patients . | Grade 3 or 4, no. (%) of patients . | P . | ||
|---|---|---|---|---|---|
| MPT . | MP . | MPT . | MP . | ||
| Constipation | 66 (37) | 47 (13) | 11 (6) | 5 (3) | .003 |
| Neuropathy | 39 (21) | 9 (6) | 10 (6) | 1 (1) | .001 |
| Nonneuropathy neurologic toxicity* | 24 (14) | 19 (11) | 14 (8) | 3 (2) | .022 |
| Exanthema | 16 (9) | 8 (4) | 4 (2) | 0 | .019 |
| Nonhematologic, altogether | 84 (47) | 54 (49) | 70 (40) | 33 (19) | .001 |
Includes tremor, ataxia, confusion, stroke, and dizziness.